Georgia CTSA Rapid Response Team: 48-Hour Approval for COVID-19 Study

Organization
Contact Email
Abstract

The Georgia CTSA Rapid Response Team expedited high-priority studies of experimental therapeutics and vaccines. Emory's first COVID-19 patient began receiving infusion therapy of Remdesivir within 48 hours as a result of Georgia CTSA's assistance in coordinating the approvals needed. Representatives from Emory research offices worked together in parallel to expedite 27 COVID-19 studies from March 2020 through September 2020. Median time from Protocol Receipt to First Subject First Visit was 20 days. This process and results are an example of how such outcomes can be attained through a common purpose, concurrent efforts by personnel at each of the offices, and strong coordination.

Authors
Amy
Stehlik
Communications Manager, Georgia CTSA